Ascertainment of EMR-based Clinical Covariates Among Patients Receiving Oral and Non-insulin Injected Hypoglycemic Therapy
NCT ID: NCT02140645
Last Updated: 2017-02-08
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
166613 participants
OBSERVATIONAL
2014-05-31
2015-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)
NCT01075282
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)
NCT01191268
A Study in Adults With Type 2 Diabetes
NCT01421459
A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes
NCT03214380
Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes
NCT00191464
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Linagliptin1
T2DM patients initiating Linagliptin (DPP-4 comparison)
linagliptin
non-randomized
Other DPP4
T2DM patients initiating a non-linagliptin DPP-4 inhibitor
No interventions assigned to this group
Linagliptin2
T2DM patients initiating Linagliptin (glitizaone comparison)
No interventions assigned to this group
Glitazones
T2DM patients initiating Thiazolidinediones (glitazones)
No interventions assigned to this group
Sulfonylurea
T2DM patients initiating any medication in the Sulfonylurea class
No interventions assigned to this group
Linagliptin3
T2DM patients initiating Linagliptin (Sulfonylurea comparison)
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
linagliptin
non-randomized
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of type 2 diabetes mellitus
* Presence of electronic medical records (for the EMR-based subset)
Exclusion Criteria
* Missing or ambiguous age or sex information
* At least one diagnosis of type 1 diabetes mellitus
* Less than 6 months enrolment in the database preceding the date of the first dispensing
* Prior use of the index drug
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Boehringer Ingelheim
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Boehringer Ingelheim
Role: STUDY_CHAIR
Boehringer Ingelheim
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Boehringer Ingelheim Investigational Site
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1218.162
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.